Terns Pharmaceuticals, Inc. (TERN) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Foster City, CA, アメリカ. 現CEOは Melita Sun Jung.
TERN を有する IPO日 2021-02-05, 59 名の正社員, に上場 NASDAQ Global Select, 時価総額 $4.75B.
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for non-alcoholic steatohepatitis (NASH) and obesity. The company's pipeline includes TERN-101, a farnesoid X receptor agonist in Phase IIa trials for NASH; TERN-201, a vascular adhesion protein-1 inhibitor in Phase Ib development; TERN-501, a thyroid hormone receptor beta agonist in Phase I trials; and TERN-601, an oral Glucagon-Like Peptide-1 receptor agonist program targeting NASH and metabolic diseases. Founded in 2016 and headquartered in Foster City, California, Terns is advancing both single-agent and combination therapy candidates to address significant unmet medical needs in metabolic disease treatment.
